The abstract is read at the publisher; the summary is JClub's.
Dupilumab treatment in eosinophilic chronic rhinosinusitis is linked to broad transcriptional remodeling in nasal polyp myeloid cells, especially cDCs, with ALOX15 downregulation.
- Why it matters: The cellular mechanisms of dupilumab within nasal polyps are unclear, despite its clinical benefit in this refractory type 2 inflammatory disease.
- What they did: Five patients provided nasal polyp and peripheral blood samples before and after dupilumab; single-cell RNA sequencing, spatial transcriptomics, immunostaining, and cDC stimulation were used to test IL-4/IL-13 receptor-dependent pathways.
- The result: IL-4/IL-13-regulated cDC responses included downregulation of ALOX15, and ALOX15 inhibition abrogated IL-4/IL-13-induced CCL13 and CCL22; after treatment, Th2, B, and plasma cell markers and TLS-like aggregates decreased.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.